Collaboration focuses on advancing eye surgeries and innovative treatments for corneal damage and cataracts
SINGAPORE – The Singapore Eye Research Institute (Seri) has entered into significant partnerships with global institutions, aiming to revolutionize ophthalmic treatments and surgical outcomes. Seri, along with the Singapore National Eye Centre (SNEC), has teamed up with Byers Eye Institute at Stanford University to develop alternatives to corneal transplants. These advancements focus on tissue engineering that could replace only damaged parts of the eye, offering targeted treatments for corneal issues caused by infections and other conditions.
The partnership will also enhance educational opportunities and clinical research in ophthalmology. One of the key projects involves developing tissue-engineered scaffolds to replace scarred corneas, using a combination of scaffolds and cells to restore vision in affected patients. Byers Eye Institute is contributing its expertise in 3D-printed tissue scaffolds, which solidify into a gel to fill in corneal defects.
Moreover, Seri has joined forces with Carl Zeiss Meditec, a leading German medtech company, to improve surgical outcomes in cataract and refractive surgeries. The partnership is backed by a nearly $20 million investment over the next three years. This collaboration will focus on advancing intraocular lenses (IOLs) to improve post-surgery outcomes and reduce complications in cataract patients.
As part of the initiatives, top trainees from Seri and SNEC will have the chance to participate in internships and fellowships at Stanford, gaining exposure to international healthcare systems. The institutions will also share expertise in artificial intelligence and digital health programs, enhancing their ability to detect and treat eye diseases.
The combined effort will also contribute to Singapore’s broader research and innovation goals under the Research, Innovation and Enterprise 2025 Plan, enhancing the nation’s capabilities in medical technology and research. These collaborations underscore Singapore’s role as a leader in ophthalmic research, with potential global impact on eye care and surgical procedures.
